Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
University of Rochester NCORP Research Base
Summary
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
Description
PRIMARY OBJECTIVE: I. Characterize differences in subjective CRCI longitudinally among patients receiving TKIs for CML or CLL. OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups. GROUP I: TKI recipients complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study. GROUP II: Cancer-free individuals complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * TKI RECIPIENTS: Participants must have a diagnosis of CML or CLL * TKI RECIPIENTS: Participants must be scheduled to receive their first dose of TKI therapy for CML or CLL within 30 days or have received their first dose of TKI therapy for CML or CLL within the previous 30 days * TKI RECIPIENTS: Participants must be ≥ 18 years of age * TKI RECIPIENTS: Participants must be able to speak and read English * TKI RECIPIENTS: Participants must be able to understand and willing to sign an informed consent document * CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must…
Location
- University of Rochester NCORP Research BaseRochester, New York